https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-24 09:04:382024-04-25 09:04:57Calliditas Announces Positive NefIgArd Open Label Extension Results
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-24 09:04:382024-04-25 09:04:57Calliditas Announces Positive NefIgArd Open Label Extension Results
https://www.optimumcomms.com/wp-content/uploads/2024/04/Flindr_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-24 08:22:552024-04-24 08:22:55Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors
https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-23 09:54:552024-04-23 09:54:55Vivet Therapeutics to Participate and Present at Upcoming Scientific and Investor Conferences in April through to June 2024
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-23 09:43:392024-04-23 14:22:18AMSilk strengthens management team with key hires of Ralph Fraundorfer and Ctibor Kohutovic to Management Board
https://www.optimumcomms.com/wp-content/uploads/2023/06/Synox_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-22 09:06:302024-04-22 09:06:30SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
https://www.optimumcomms.com/wp-content/uploads/2024/04/Outrun_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-18 08:38:512024-04-18 08:42:50Outrun Therapeutics launches with a $10m seed financing from M Ventures and MP Healthcare Venture Management to develop a protein stabilisation pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-18 08:36:492024-04-18 08:36:494SC publishes Q1 2024 report
https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-17 14:17:182024-04-17 14:41:42Xeltis Announces Latest Results from aXess Trials to be Presented at 46th Annual Charing Cross Symposium
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-15 10:51:362024-04-15 10:51:364SC AG: Paediatric Investigation Plan waiver for resminostat from the UK MHRA received
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-11 08:44:152024-04-11 08:44:154SC: Landmark RESMAIN study data presented at the 5th World Congress of Cutaneous Lymphomas
https://www.optimumcomms.com/wp-content/uploads/2023/06/SpliceBio_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-10 14:47:262024-04-10 14:47:26SpliceBio to Attend and Present at Key Scientific and Investor Conferences in April to June 2024
https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-08 10:34:212024-04-08 10:34:21Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease
https://www.optimumcomms.com/wp-content/uploads/2023/02/Medicxi_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-08 08:12:222024-04-08 08:13:04Medicxi Announces $40m investment in D3 Bio
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-05 08:35:292024-04-05 08:35:29Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-04 08:53:322024-04-04 08:53:32Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024
https://www.optimumcomms.com/wp-content/uploads/2023/06/adcendo_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-04 08:44:102024-04-04 08:44:10Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
